[Report] Advanced Drug Delivery Systems Market Research, Trends, Analysis TOC

INTRODUCTION
- STUDY OBJECTIVES
- REASONS FOR DOING THIS STUDY
- CONTRIBUTIONS OF THE STUDY AND FOR WHOM
- SCOPE OF THE STUDY
- METHODOLOGY
- INFORMATION SOURCES
- ABOUT THE AUTHOR
- RELATED BCC REPORTS
- DISCLAIMER
EXECUTIVE SUMMARY
- Summary Table:
- U.S. MARKET FORECAST OF ADVANCED DRUG DELIVERY SYSTEMS THROUGH 2011 ($ BILLIONS)
- Summary Figure:
- U.S. MARKET FOR ADVANCED DRUG DELIVERY SYSTEMS 2004-2011 ($ BILLIONS)
OVERVIEW
- DOSAGE FORMS
  - DIFFERENT TYPES OF DOSAGE FORMS
- WHAT IS DRUG DELIVERY?
  - ROUTES OF DRUG DELIVERY
  - TECHNOLOGIES FOR DRUG DELIVERY
    - Sustained Release
    - Delayed Release
    - Prodrugs
    - Implants and Pumps for Drug Delivery
    - Targeted Delivery Systems
    - Receptor-Mediated Targeted Drug Delivery
  - CLASSIFICATION OF DRUG DELIVERY SYSTEMS
REGULATORY ISSUES
- THE ROLE OF REGULATORY AUTHORITIES IN DRUG DELIVERY
- Table 1 REGULATORY ACTION TAKEN FOR SAFE DRUG USAGE FOR DRUG DELIVERY SYSTEMS
  - USE OF EXCIPIENTS
INDUSTRY STRUCTURE
- DRUG DELIVERY SYSTEMS PRODUCT SEGMENTS
- SUSTAINED RELEASE ORAL DOSAGE FORMS
  - DIFFUSIONAL AND DISSOLUTION SYSTEMS
  - MARKET LEADERS
- Table 2 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED RELEASE ORAL DOSAGE FORMS, 2005
- Table 3 U.S. MARKET FOR SUSTAINED RELEASE ORAL DOSAGE FORMS BY MANUFACTURER, 2005 (%)
- Figure 1 U.S. MARKET SHARE FOR SUSTAINED RELEASE ORAL DOSAGE FORMS BY MANUFACTURER, 2005 (%)
  - SUSTAINED RELEASE INJECTABLE DOSAGE FORMS
    - MARKET LEADERS
- Table 4 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED RELEASE INJECTABLE DOSAGE FORMS, 2005
- Table 5 U.S. SUSTAINED RELEASE INJECTABLE DOSAGE FORM MARKET BY MANUFACTURER, 2005 (%)
- Figure 2 U.S. SUSTAINED RELEASE INJECTABLE DOSAGE FORMS MARKET BY MANUFACTURER, 2005 (%)
  - SUSTAINED RELEASE TOPICAL DOSAGE FORMS
    - MARKET LEADERS
- Table 6 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED RELEASE TOPICAL DOSAGE FORMS, 2005
- Table 7 U.S. MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS BY MANUFACTURER, 2005 (%)
- Figure 3 U.S.MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS BY MANUFACTURER, 2005 (%)
  - IMPLANTS AND IUDS
    - MARKET LEADERS
- Table 8 MAJOR SUPPLIERS AND MANUFACTURERS OF IMPLANTS AND IUDS
- Table 9 U.S. MARKET FOR IMPLANTS AND IUDS BY MANUFACTURER, 2005 (%)
- Figure 4 U.S. MARKET FOR IMPLANTS AND IUDS BY MANUFACTURER, 2005 (%)
  - TRANSDERMAL DRUG DELIVERY SYSTEM (TDDS)
    - MARKET LEADERS
- Table 10 MAJOR SUPPLIERS AND MANUFACTURERS OF TRANSDERMAL DRUG DELIVERY SYSTEMS, 2005
- Table 11 U.S. MARKET FOR PATCH-DELIVERED DRUGS USED IN TRANSDERMAL DRUG DELIVERY SYSTEMS BY TYPE, 2005 (%)
- Figure 5 U.S MARKET FOR PATCH DELIVERED DRUGS USED IN TRANSDERMAL DRUG DELIVERY SYSTEMS BY TYPE, 2005 (%)
- Table 12 U.S. MARKET FOR SUPPLIERS AND MANUFACTURERS OF TDDS, 2005 (%)
- Figure 6 U.S. MARKET FOR TDDS BY MANUFACTURER, 2005 (%)
  - TARGETED DELIVERY SYSTEMS
    - LIPOSOMES
    - MARKET LEADERS
- Table 13 MAJOR SUPPLIERS AND MANUFACTURERS OF LIPOSOMES, 2005
- Table 14 U.S. LIPOSOME DRUG MARKET BY TYPE, 2005 (%)
- Figure 7 U.S LIPOSOME DRUG MARKET BY TYPE, 2005 (%)
- Table 15 U.S. LIPOSOME MARKET BY MANUFACTURER, 2005 (%)
- Figure 8 U.S. LIPOSOME MARKET BY MANUFACTURER, 2005 (%)
  - NANOPARTICLES
- Table 16 MAJOR SUPPLIERS AND MANUFACTURERS OF NANOPARTICLES, 2005
- Table 17 U.S. NANOPARTICLE MARKET BY MANUFACTURER, 2005 (%)
- Figure 9 U.S. NANOPARTICLE MARKET BY MANUFACTURER, 2005 (%)
  - POLYMERS
    - MARKET LEADERS
- Table 18 MAJOR SUPPLIERS AND MANUFACTURERS OF POLYMERS, 2005
  - MONOCLONAL ANTIBODIES
    - MARKET LEADERS
- Table 19 MAJOR SUPPLIERS AND MANUFACTURERS OF MONOCLONAL ANTIBODIES, 2005
- Table 20 U.S. MARKET FOR MONOCLONAL ANTIBODIES BY MANUFACTURER, 2005 (%)
- Figure 10 U.S. MARKET FOR MONOCLONAL ANTIBODIES, BY MANUFACTURER, 2005 (%)
  - PEGNOLOGY
    - MARKET LEADERS
- Table 21 MAJOR SUPPLIERS AND MANUFACTURERS OF PEGNOLOGY, 2005
- Table 22 U.S. MARKET FOR PEGNOLOGY BY MANUFACTURER, 2005 (%)
- Figure 11 U.S. MARKET FOR PEGNOLOGY BY MANUFACTURER, 2005 (%)
  - TRANSMUCOSAL DRUG DELIVERY SYSTEMS
  - INHALATION SYSTEMS
    - MARKET LEADERS
- Table 23 MAJOR SUPPLIERS AND MANUFACTURERS OF INHALATION SYSTEMS, 2005
- Table 24 U.S. MARKET FOR INHALATION SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 12 U.S. MARKET FOR INHALATION SYSTEMS BY MANUFACTURER, 2005 (%)
  - BUCCAL DELIVERY
    - MARKET LEADERS
- Table 25 MAJOR SUPPLIERS AND MANUFACTURERS OF BUCCAL DELIVERY SYSTEMS, 2005
- Table 26 U.S. MARKET FOR BUCCAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 13 U.S. MARKET SHARE FORBUCCAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
  - RECTAL DELIVERY
    - MARKET LEADERS
- Table 27 MAJOR SUPPLIERS AND MANUFACTURERS OF RECTAL DELIVERY SYSTEMS, 2005
- Table 28 U.S. MARKET FOR RECTAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 14 U.S. MARKET FOR RECTAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
  - VAGINAL DELIVERY
    - MARKET LEADERS
- Table 29 MAJOR SUPPLIERS AND MANUFACTURERS OF VAGINAL DELIVERY SYSTEMS, 2005
- Table 30 U.S. MARKET FOR VAGINAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 15 U.S. MARKET FORVAGINAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
  - OCULAR DELIVERY
  - MARKET LEADERS
- Table 31 MAJOR SUPPLIERS AND MANUFACTURERS OF OCULAR DELIVERY SYSTEMS, 2005
- Table 32 U.S. MARKET FOR OCULAR DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 16 U.S. MARKET FOROCULAR DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
  - OTHERS
    - VACCINES
    - POLYCLONAL ANTIBODIES
  - FACTORS GOVERNING DEMAND AND USE
    - IMPROVING EFFICACY
    - ENVIRONMENTAL CONCERNS
    - BENEFITS OF DRUG DELIVERY
      - Compliance
      - Efficacy and Safety
      - Benefits to Pharmaceutical and Biotech Companies
      - Rescuing Research and Development Dropouts
      - Reducing Side Effects
TECHNOLOGY
- NEW PRODUCT DEVELOPMENTS
- Table 33 DEVELOPMENTS IN SUSTAINED RELEASE ORAL DOSAGE FORMS
- Table 34 DEVELOPMENTS IN SUSTAINED RELEASE INJECTABLE DOSAGE FORMS
- Table 35 DEVELOPMENTS IN SUSTAINED RELEASE TOPICAL DOSAGE FORMS
- Table 36 DEVELOPMENTS IN TRANSDERMAL DRUG DELIVERY SYSTEMS
- Table 37 DEVELOPMENTS IN LIPOSOMES
- Table 38 DEVELOPMENTS IN NANOPARTICLES
- Table 39 DEVELOPMENTS IN POLYMER
- Table 40 DEVELOPMENTS IN MONOCLONAL ANTIBODIES
- Table 41 DEVELOPMENTS IN PEGNOLOGY
- Table 42 DEVELOPMENTS IN INHALATION SYSTEMS
- Table 43 DEVELOPMENTS IN BUCCAL DELIVERY
- Table 44 DEVELOPMENTS IN VAGINAL DELIVERY
- Table 45 DEVELOPMENTS IN OCULAR DELIVERY
- Table 46 DEVELOPMENTS IN VACCINE DELIVERY
MARKETS FOR DRUG DELIVERY TECHNOLOGY
- SUSTAINED RELEASE ORAL DOSAGE FORM
  - PELLETIZED PULSATILE DELIVERY SYSTEM
  - SINGLE COMPOSITION OSMOTIC TABLET SYSTEM
  - SOLUBILITY MODULATING HYDROGEL SYSTEM
  - DELAYED PULSATILE HYDOGEL SYSTEM (DPHS)
  - STABILIZED PELLET DELIVERY SYSTEM
  - GRANULATED MODULATING HYDROGEL SYSTEM
  - PELLETIZED TABLET SYSTEM
  - POROUS TABLET SYSTEM
  - STABILIZED TABLET DELIVERY SYSTEM
  - DIRECTLY COMPRESSIBLE HYDROGEL SYSTEM
  - MODULATING MATRIX SYSTEM
  - PULSATILE ENTERIC COATING SYSTEM
  - PELLETIZED DELIVERY SYSTEM
- Table 47 U.S. MARKET FORECAST FOR SUSTAINED RELEASE ORAL DOSAGE FORMS, THROUGH 2011 ($ BILLIONS)
- Figure 17 U.S. MARKET FOR SUSTAINED RELEASE ORAL DOSAGE FORMS, 2004-2011 ($ BILLIONS)
  - SUSTAINED RELEASE INJECTABLE DOSAGE FORM
- Table 48 U.S. MARKET FORECAST FOR SUSTAINED RELEASE INJECTABLE DOSAGE FORMS, THROUGH 2011 ($ BILLIONS)
- Figure 18 U.S. MARKET FOR SUSTAINED RELEASE INJECTABLE DOSAGE FORMS ($ BILLIONS)
  - SUSTAINED RELEASE TOPICAL DOSAGE FORMS
- Table 49 U.S. MARKET FORECAST FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS, THROUGH 2011 ($ MILLIONS)
- Figure 19 U.S. MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS, 2004-2011 ($ MILLIONS)
  - IMPLANTS AND INTRAUTRINE DEVICES (IUDS)
- Table 50 U.S. MARKET FORECAST FOR IMPLANTS AND IUDS, THROUGH 2011 ($ BILLIONS)
- Figure 20 U.S. MARKET FOR IMPLANTS AND IUDS, 2004-2011 ($ BILLIONS)
  - TRANSDERMAL DRUG DELIVERY SYSTEMS
- Table 51 U.S. MARKET FORECAST FOR TDDS, THROUGH 2011 ($ BILLIONS)
- Figure 21 U.S. MARKET FOR TDDS, 2004-2011 ($ BILLIONS)
  - TARGETED DELIVERY SYSTEMS
- Table 52 U.S. MARKET FORECAST FOR TARGETED DELIVERY SYSTEMS, THROUGH 2011 ($ MILLIONS)
- Figure 22 U.S. MARKET FOR TARGETED DELIVERY SYSTEMS 2004-2011 ($ MILLIONS)
  - TRANSMUCOSAL DELIVERY SYSTEMS
- Table 53 U.S. MARKET FORECAST FOR TRANSMUCOSAL DELIVERY SYSTEMS, THROUGH 2011 ($ MILLIONS)
- Figure 23 U.S. MARKET FOR TRANSMUCOSAL DELIVERY SYSTEMS, 2004-2011 ($ MILLIONS)
PATENTS
- PATENTS BY YEAR
- Table 54 ANNUAL NUMBER OF PATENTS, 2003-2006
- Figure 24 ANNUAL NUMBER OF PATENTS, 2003-2006 (UNITS)
- Figure 25 ANNUAL NUMBER OF PATENTS, 2003-2005 (%)
  - PATENTS BY TECHNOLOGY
- Table 55 DRUG DELIVERY PATENTS BY CATEGORY, 2003-2006
- Figure 26 NUMBER OF DRUG DELIVERY PATENTS BY CATEGORY, 2003-2006 (UNITS)
- Figure 27 DRUG DELIVERY PATENTS BY CATEGORY, 2003-2006 (%)
  - SIGNIFICANT PATENTS OF 2006
- Table 56 SIGNIFICANT PATENTS FOR DRUG DELIVERY, 2006
  - PATENTS BY COMPANY
- Table 57 U.S. PATENTS BY COMPANY, 2003-2006 (UNITS)
  - PATENTS BY COUNTRY
- Table 58 NUMBER OF DRUG DELIVERY PATENTS BY COUNTRY, 2003-2006
- Table 59 TRENDS OF DRUG DELIVERY PATENTS ISSUED BY COUNTRY, 2003-2006 (UNITS/%)
  - PATENTS BY ASSIGNEE
- Table 60 SHARES OF U.S. PATENTS BY ASSIGNEE, 2003-2006 (UNIT/%)
- Figure 28 SHARES OF U.S. PATENTS BY ASSIGNEE, 2003-2006 (UNITS)
- Figure 29 SHARES OF U.S. PATENTS BY ASSIGNEE, 2003-2006 (%)
MARKETS BY PRODUCT
- MARKETS BY PRODUCT
- Table 61 U.S. MARKET FOR DRUG DELIVERY SYSTEMS BY PRODUCT SEGMENT, 2005 (%)
  - CARDIOVASCULAR
- Table 62 U.S. MARKET FORECAST FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 30 U.S. MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
  - ONCOLOGY
- Table 63 U.S. MARKET FORECAST FOR ONCOLOGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 31 U.S. MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEM, 2004-2011 ($ BILLIONS)
  - UROLOGY
- Table 64 U.S. MARKET FORECAST FOR UROLOGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 32 U.S. MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
  - DIABETES
- Table 65 U.S. MARKET FORECAST FOR DIABETES DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 33 U.S. MARKT FOR DIABETES DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
  - RESPIRATORY
- Table 66 U.S. MARKET FORECAST FOR RESPIRATORY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 34 U.S. MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
  - ANTI-INFLAMMATORY AND ALLERGY DRUG DELIVERY
- Table 67 U.S. MARKET FORECAST FOR ANTI-INFLAMMATORY AND ALLERGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 35 U.S. MARKET FOR ANTI-INFLAMMATORY AND ALLERGY DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
  - ANTIBIOTICS
- Table 68 U.S. MARKET FORECAST FOR ANTIBIOTIC DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 36 U.S. MARKET FOR ANTIBIOTIC DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
  - ANTI-ANXIETY AND ANTI-DEPRESSANTS
- Table 69 U.S. MARKET FORECAST FOR ANTIANXIETY AND ANTIDEPRESSANT DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 37 U.S. MARKET FOR ANTI-ANXIETY AND ANTI-DEPRESSANT DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
  - HORMONES AND GYNECOLOGY
- Table 70 U.S. MARKET FOR HORMONE AND GYNECOLOGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 38 U.S. MARKET FOR HORMONES AND GYNECOLOGY DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
  - OPHTHALMIC
- Table 71 U.S. MARKET FORECAST FOR OPHTHALMIC DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 39 U.S. MARKET FOR OPHTHALMIC DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
  - IMMUNE DISEASES
- Table 72 U.S. MARKET FORECAST FOR IMMUNE DISEASEDRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 40 U.S. MARKET FOR IMMUNE DISEASEDRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLION)
  - OTHERS
- Table 73 U.S. MARKET FORECAST FOR OTHERS CATEGORY IN DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 41 U.S. MARKET FOR OTHERS CATEGORY IN DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Table 74 U.S. MARKET SHARES OF DEVELOPMENTS IN DRUG DELIVERY SYSTEMS, 2005 (%)
INTERNATIONAL ASPECTS
- ASIA
- EUROPE
- REGIONAL COMPARISONS
- Table 75 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS, 2005 (%)
- Figure 42 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS, 2005 (%)
  - SUSTAINED RELEASE DOSAGE FORM (ORAL, INJECTABLE, TOPICAL) DRUG DELIVERY SYSTEMS
- Table 76 GLOBAL MARKET FORECAST FOR SUSTAINED RELEASE DOSAGE (ORAL, INJECTABLE, TOPICAL) DRUG DELIVERY SYSTEMS BY REGION, THROUGH 2011 ($ BILLIONS)
- Figure 43 GLOBAL MARKET FOR SUSTAINED RELEASE DOSAGE (ORAL, INJECTABLE, TOPICAL) DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
  - IMPLANTS AND IUDS DRUG DELIVERY SYSTEMS
- Table 77 GLOBAL MARKET FORECAST FOR IMPLANT AND IUD DRUG DELIVERY SYSTEMS BY REGION, THROUGH 2011 ($ BILLIONS)
- Figure 44 GLOBAL MARKET FOR IMPLANTS AND IUD DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
  - TRANSDERMAL DRUG DELIVERY SYSTEMS
- Table 78 GLOBAL MARKET FORECAST FOR TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 45 GLOBAL MARKET FORECAST FOR TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
  - TARGETED DRUG DELIVERY SYSTEM, THROUGH 2011
- Table 79 GLOBAL MARKET FORECAST FOR TARGETED DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 46 GLOBAL MARKET FOR TARGETED DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
  - GLOBAL MARKET FOR Transmucosal Drug Delivery SYSTEMS THROUGH 2011
- Table 80 GLOBAL MARKET FORECAST FOR TRANSMUCOSAL DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 47 GLOBAL MARKET FOR TRANSMUCOSAL DRUG DELIVERY SYSTEMS 2004-2011 ($ BILLION)
COMPANY PROFILES
- ABBOTT LABORATORIES
- APP-ABRAXIS PHARMACEUTICAL PRODUCTS
- ASTRAZENECA PHARMACEUTICALS
- ALKERMES
- ADVANCED POLYMER PHARMA INC. (A.P. PHARMA)
- AVENTIS PHARMACEUTICAL INC.
- AKORN INC.
- ANTIGENICS INC.
- ARADIGM CORP.
- ANDRX CORP. (ACQUIRED BY WATSON IN 2006)
- BAYER CORP.
- BIOVAIL CORP.
- BERLEX LABORATORIES, INC.
- BIOSANTE PHARMACEUTICALS, INC.
- CARDINAL HEALTH, INC.
- ELAN
- ENZON, INC.
- EURAND
- GENENTECH INC.
- GILEAD
- JOHNSON & JOHNSON
- KV PHARMACEUTICAL CO.
- 3M PHARMACEUTICALS
- MEDIMMUNE, INC.
- MGI PHARMA
- MYLAN LABORATORIES INC.
- NEKTAR THERAPEUTICS
- NOVEN PHARMACEUTICALS, INC.
- NOVAVAX, INC.
- PFIZER INC.
- PROTEIN DESIGN LABS
- QLT USA INC.
- SONTRA MEDICAL CORP.
- SCHERING-PLOUGH CORP.
- SOUTHERN RESEARCH INSTITUTE
- SKYEPHARMA
- WATSON PHARMACEUTICALS, INC.
- WYETH
LIST OF TABLES
- Summary Table:
- U.S. MARKET FORECAST OF ADVANCED DRUG DELIVERY SYSTEMS THROUGH 2011 ($ BILLIONS)
- Table 1 REGULATORY ACTION TAKEN FOR SAFE DRUG USAGE FOR DRUG DELIVERY SYSTEMS
- Table 2 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED RELEASE ORAL DOSAGE FORMS, 2005
- Table 3 U.S. MARKET FOR SUSTAINED RELEASE ORAL DOSAGE FORMS BY MANUFACTURER, 2005 (%)
- Table 4 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED RELEASE INJECTABLE DOSAGE FORMS, 2005
- Table 5 U.S. SUSTAINED RELEASE INJECTABLE DOSAGE FORM MARKET BY MANUFACTURER, 2005 (%)
- Table 6 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED RELEASE TOPICAL DOSAGE FORMS, 2005
- Table 7 U.S. MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS BY MANUFACTURER, 2005 (%)
- Table 8 MAJOR SUPPLIERS AND MANUFACTURERS OF IMPLANTS AND IUDS
- Table 9 U.S. MARKET FOR IMPLANTS AND IUDS BY MANUFACTURER, 2005 (%)
- Table 10 MAJOR SUPPLIERS AND MANUFACTURERS OF TRANSDERMAL DRUG DELIVERY SYSTEMS, 2005
- Table 11 U.S. MARKET FOR PATCH-DELIVERED DRUGS USED IN TRANSDERMAL DRUG DELIVERY SYSTEMS BY TYPE, 2005 (%)
- Table 12 U.S. MARKET FOR SUPPLIERS AND MANUFACTURERS OF TDDS, 2005 (%)
- Table 13 MAJOR SUPPLIERS AND MANUFACTURERS OF LIPOSOMES, 2005
- Table 14 U.S. LIPOSOME DRUG MARKET BY TYPE, 2005 (%)
- Table 15 U.S. LIPOSOME MARKET BY MANUFACTURER, 2005 (%)
- Table 16 MAJOR SUPPLIERS AND MANUFACTURERS OF NANOPARTICLES, 2005
- Table 17 U.S. NANOPARTICLE MARKET BY MANUFACTURER, 2005 (%)
- Table 18 MAJOR SUPPLIERS AND MANUFACTURERS OF POLYMERS, 2005
- Table 19 MAJOR SUPPLIERS AND MANUFACTURERS OF MONOCLONAL ANTIBODIES, 2005
- Table 20 U.S. MARKET FOR MONOCLONAL ANTIBODIES BY MANUFACTURER, 2005 (%)
- Table 21 MAJOR SUPPLIERS AND MANUFACTURERS OF PEGNOLOGY, 2005
- Table 22 U.S. MARKET FOR PEGNOLOGY BY MANUFACTURER, 2005 (%)
- Table 23 MAJOR SUPPLIERS AND MANUFACTURERS OF INHALATION SYSTEMS, 2005
- Table 24 U.S. MARKET FOR INHALATION SYSTEMS BY MANUFACTURER, 2005 (%)
- Table 25 MAJOR SUPPLIERS AND MANUFACTURERS OF BUCCAL DELIVERY SYSTEMS, 2005
- Table 26 U.S. MARKET FOR BUCCAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Table 27 MAJOR SUPPLIERS AND MANUFACTURERS OF RECTAL DELIVERY SYSTEMS, 2005
- Table 28 U.S. MARKET FOR RECTAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Table 29 MAJOR SUPPLIERS AND MANUFACTURERS OF VAGINAL DELIVERY SYSTEMS, 2005
- Table 30 U.S. MARKET FOR VAGINAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Table 31 MAJOR SUPPLIERS AND MANUFACTURERS OF OCULAR DELIVERY SYSTEMS, 2005
- Table 32 U.S. MARKET FOR OCULAR DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Table 33 DEVELOPMENTS IN SUSTAINED RELEASE ORAL DOSAGE FORMS
- Table 34 DEVELOPMENTS IN SUSTAINED RELEASE INJECTABLE DOSAGE FORMS
- Table 35 DEVELOPMENTS IN SUSTAINED RELEASE TOPICAL DOSAGE FORMS
- Table 36 DEVELOPMENTS IN TRANSDERMAL DRUG DELIVERY SYSTEMS
- Table 37 DEVELOPMENTS IN LIPOSOMES
- Table 38 DEVELOPMENTS IN NANOPARTICLES
- Table 39 DEVELOPMENTS IN POLYMER
- Table 40 DEVELOPMENTS IN MONOCLONAL ANTIBODIES
- Table 41 DEVELOPMENTS IN PEGNOLOGY
- Table 42 DEVELOPMENTS IN INHALATION SYSTEMS
- Table 43 DEVELOPMENTS IN BUCCAL DELIVERY
- Table 44 DEVELOPMENTS IN VAGINAL DELIVERY
- Table 45 DEVELOPMENTS IN OCULAR DELIVERY
- Table 46 DEVELOPMENTS IN VACCINE DELIVERY
- Table 47 U.S. MARKET FORECAST FOR SUSTAINED RELEASE ORAL DOSAGE FORMS, THROUGH 2011 ($ BILLIONS)
- Table 48 U.S. MARKET FORECAST FOR SUSTAINED RELEASE INJECTABLE DOSAGE FORMS, THROUGH 2011 ($ BILLIONS)
- Table 49 U.S. MARKET FORECAST FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS, THROUGH 2011 ($ MILLIONS)
- Table 50 U.S. MARKET FORECAST FOR IMPLANTS AND IUDS, THROUGH 2011 ($ BILLIONS)
- Table 51 U.S. MARKET FORECAST FOR TDDS, THROUGH 2011 ($ BILLIONS)
- Table 52 U.S. MARKET FORECAST FOR TARGETED DELIVERY SYSTEMS, THROUGH 2011 ($ MILLIONS)
- Table 53 U.S. MARKET FORECAST FOR TRANSMUCOSAL DELIVERY SYSTEMS, THROUGH 2011 ($ MILLIONS)
- Table 54 ANNUAL NUMBER OF PATENTS, 2003-2006
- Table 55 DRUG DELIVERY PATENTS BY CATEGORY, 2003-2006
- Table 56 SIGNIFICANT PATENTS FOR DRUG DELIVERY, 2006
- Table 57 U.S. PATENTS BY COMPANY, 2003-2006 (UNITS)
- Table 58 NUMBER OF DRUG DELIVERY PATENTS BY COUNTRY, 2003-2006
- Table 59 TRENDS OF DRUG DELIVERY PATENTS ISSUED BY COUNTRY, 2003-2006 (UNITS/%)
- Table 60 SHARES OF U.S. PATENTS BY ASSIGNEE, 2003-2006 (UNIT/%)
- Table 61 U.S. MARKET FOR DRUG DELIVERY SYSTEMS BY PRODUCT SEGMENT, 2005 (%)
- Table 62 U.S. MARKET FORECAST FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 63 U.S. MARKET FORECAST FOR ONCOLOGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 64 U.S. MARKET FORECAST FOR UROLOGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 65 U.S. MARKET FORECAST FOR DIABETES DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 66 U.S. MARKET FORECAST FOR RESPIRATORY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 67 U.S. MARKET FORECAST FOR ANTI-INFLAMMATORY AND ALLERGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 68 U.S. MARKET FORECAST FOR ANTIBIOTIC DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 69 U.S. MARKET FORECAST FOR ANTIANXIETY AND ANTIDEPRESSANT DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 70 U.S. MARKET FOR HORMONE AND GYNECOLOGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 71 U.S. MARKET FORECAST FOR OPHTHALMIC DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 72 U.S. MARKET FORECAST FOR IMMUNE DISEASEDRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 73 U.S. MARKET FORECAST FOR OTHERS CATEGORY IN DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 74 U.S. MARKET SHARES OF DEVELOPMENTS IN DRUG DELIVERY SYSTEMS, 2005 (%)
- Table 75 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS, 2005 (%)
- Table 76 GLOBAL MARKET FORECAST FOR SUSTAINED RELEASE DOSAGE (ORAL, INJECTABLE, TOPICAL) DRUG DELIVERY SYSTEMS BY REGION, THROUGH 2011 ($ BILLIONS)
- Table 77 GLOBAL MARKET FORECAST FOR IMPLANT AND IUD DRUG DELIVERY SYSTEMS BY REGION, THROUGH 2011 ($ BILLIONS)
- Table 78 GLOBAL MARKET FORECAST FOR TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 79 GLOBAL MARKET FORECAST FOR TARGETED DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 80 GLOBAL MARKET FORECAST FOR TRANSMUCOSAL DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
LIST OF FIGURES
- Summary Figure:
- U.S. MARKET FOR ADVANCED DRUG DELIVERY SYSTEMS 2004-2011 ($ BILLIONS)
- Figure 1 U.S. MARKET SHARE FOR SUSTAINED RELEASE ORAL DOSAGE FORMS BY MANUFACTURER, 2005 (%)
- Figure 2 U.S. SUSTAINED RELEASE INJECTABLE DOSAGE FORMS MARKET BY MANUFACTURER, 2005 (%)
- Figure 3 U.S.MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS BY MANUFACTURER, 2005 (%)
- Figure 4 U.S. MARKET FOR IMPLANTS AND IUDS BY MANUFACTURER, 2005 (%)
- Figure 5 U.S MARKET FOR PATCH DELIVERED DRUGS USED IN TRANSDERMAL DRUG DELIVERY SYSTEMS BY TYPE, 2005 (%)
- Figure 6 U.S. MARKET FOR TDDS BY MANUFACTURER, 2005 (%)
- Figure 7 U.S LIPOSOME DRUG MARKET BY TYPE, 2005 (%)
- Figure 8 U.S. LIPOSOME MARKET BY MANUFACTURER, 2005 (%)
- Figure 9 U.S. NANOPARTICLE MARKET BY MANUFACTURER, 2005 (%)
- Figure 10 U.S. MARKET FOR MONOCLONAL ANTIBODIES, BY MANUFACTURER, 2005 (%)
- Figure 11 U.S. MARKET FOR PEGNOLOGY BY MANUFACTURER, 2005 (%)
- Figure 12 U.S. MARKET FOR INHALATION SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 13 U.S. MARKET SHARE FORBUCCAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 14 U.S. MARKET FOR RECTAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 15 U.S. MARKET FORVAGINAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 16 U.S. MARKET FOROCULAR DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 17 U.S. MARKET FOR SUSTAINED RELEASE ORAL DOSAGE FORMS, 2004-2011 ($ BILLIONS)
- Figure 18 U.S. MARKET FOR SUSTAINED RELEASE INJECTABLE DOSAGE FORMS ($ BILLIONS)
- Figure 19 U.S. MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS, 2004-2011 ($ MILLIONS)
- Figure 20 U.S. MARKET FOR IMPLANTS AND IUDS, 2004-2011 ($ BILLIONS)
- Figure 21 U.S. MARKET FOR TDDS, 2004-2011 ($ BILLIONS)
- Figure 22 U.S. MARKET FOR TARGETED DELIVERY SYSTEMS 2004-2011 ($ MILLIONS)
- Figure 23 U.S. MARKET FOR TRANSMUCOSAL DELIVERY SYSTEMS, 2004-2011 ($ MILLIONS)
- Figure 24 ANNUAL NUMBER OF PATENTS, 2003-2006 (UNITS)
- Figure 25 ANNUAL NUMBER OF PATENTS, 2003-2005 (%)
- Figure 26 NUMBER OF DRUG DELIVERY PATENTS BY CATEGORY, 2003-2006 (UNITS)
- Figure 27 DRUG DELIVERY PATENTS BY CATEGORY, 2003-2006 (%)
- Figure 28 SHARES OF U.S. PATENTS BY ASSIGNEE, 2003-2006 (UNITS)
- Figure 29 SHARES OF U.S. PATENTS BY ASSIGNEE, 2003-2006 (%)
- Figure 30 U.S. MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 31 U.S. MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEM, 2004-2011 ($ BILLIONS)
- Figure 32 U.S. MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 33 U.S. MARKT FOR DIABETES DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 34 U.S. MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 35 U.S. MARKET FOR ANTI-INFLAMMATORY AND ALLERGY DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 36 U.S. MARKET FOR ANTIBIOTIC DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 37 U.S. MARKET FOR ANTI-ANXIETY AND ANTI-DEPRESSANT DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 38 U.S. MARKET FOR HORMONES AND GYNECOLOGY DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 39 U.S. MARKET FOR OPHTHALMIC DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 40 U.S. MARKET FOR IMMUNE DISEASEDRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLION)
- Figure 41 U.S. MARKET FOR OTHERS CATEGORY IN DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 42 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS, 2005 (%)
- Figure 43 GLOBAL MARKET FOR SUSTAINED RELEASE DOSAGE (ORAL, INJECTABLE, TOPICAL) DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 44 GLOBAL MARKET FOR IMPLANTS AND IUD DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 45 GLOBAL MARKET FORECAST FOR TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 46 GLOBAL MARKET FOR TARGETED DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 47 GLOBAL MARKET FOR TRANSMUCOSAL DRUG DELIVERY SYSTEMS 2004-2011 ($ BILLION)

Advanced Drug Delivery Systems: New Developments, New Technologies

Table of Contents